Intra Cellular Therapies reported $0 in Loan Capital for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
Acadia Pharmaceuticals ACAD:US $ 0M 0M
ALKERMES ALKS:US 294.07M 632K
Aptinyx Inc APTX:US $ 0 0
Arena Pharmaceuticals ARNA:US $ 38.78M 1.25M
Biocryst Pharmaceuticals BCRX:US $ 263.66M 9.32M
Biogen BIIB:US $ 6272.3M 996.9M
Bristol Myers Squibb BMY:US $ 42503M 2002M
Cytokinetics CYTK:US $ 127.89M 3.88M
Esperion Therapeutics ESPR:US $ 272.1M 404K
Gw Pharmaceuticals GWPH:US $ 14.16M 0.14M
Halozyme Therapeutics HALO:US $ 785.57M 0.84M
Intra Cellular Therapies ITCI:US $ 0M 0M
JAZZ PHA JAZZ:US $ 6495.33M 4642.3M
Marinus Pharmaceuticals MRNS:US $ 10.97M 10.97M
Minerva Neurosciences NERV:US $ 0M 0M
Nektar Therapeutics NKTR:US $ 0M 0M
Neurocrine Biosciences NBIX:US $ 326.3M 4.3M
Novartis NVS:US $ 26491M 908M
Prothena PRTA:US 0 0
Redhill Biopharma RDHL:US $ 86.14M 0.22M
Supernus Pharmaceuticals SUPN:US $ 370.38M 14.15M
United Therapeutics UTHR:US $ 800M 0M
Vanda Pharmaceuticals VNDA:US $ 0M 0M
Zogenix ZGNX:US $ 153.63M 2.18M